Recombinant human erythropoietin in patients with myelodysplastic syndromes.

Treatment with mycophenolate mofetil followed by recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes resistant to erythropoietin treatment.

rHuEpo administration in patients with low-risk myelodysplastic syndromes: evaluation of erythroid precur-

controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies. J Clin Oncol 2002;20: 2486-94. 12. Cazzola M, Beguin Y, Kloczko J, Spicka I, Coiffier B. Onceweekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production. Br J Haematol 2003, in press. 13. Pangalis GA, Sia...

Myelodysplastic Syndromes Adding growth factors or interleukin-3 to erythropoietin has limited effects on ane- mia of transfusion-dependent patients with myelodysplastic syndromes unre- sponsive to erythropoietin alone

Background and Objectives. Recombinant erythropoietin (r-EPO) induces erythroid responses in patients affected by myelodysplastic syndromes (MDS). However, the response rate declines to 10-15% in MDS with substantial transfusion needs. Both in vitro and in vivo studies have suggested that the addition of growth factors (GCSF, GM-CSF) or interleukin-3 (IL-3) may potentiate the effect of r-EPO on...

Efficacy of lenalidomide in myelodysplastic syndromes.

BACKGROUND Ineffective erythropoiesis is the hallmark of myelodysplastic syndromes. Management of the anemia caused by ineffective erythropoiesis is difficult. In patients with myelodysplastic syndromes and symptomatic anemia, we evaluated the safety and hematologic activity of lenalidomide, a novel analogue of thalidomide. METHODS Forty-three patients with transfusion-dependent or symptomati...

Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy.

Patients with myelodysplastic syndromes (MDS) have refractory cytopenias leading to transfusion requirements and infectious complications. In vitro marrow culture data have indicated that granulocyte colony stimulating factor (G-CSF) synergizes with erythropoietin (EPO) for the production of erythroid precursors. In an effort to treat the anemia and neutropenia in this disorder, MDS patients we...

Combined therapy with amifostine plus erythropoietin for the treatment of myelodysplastic syndromes.

Twelve patients with myelodysplasia were treated with amifostine plus recombinant human erythropoietin (rHuEpo) for 6 weeks. A complete erythroid response was obtained in 2/12(16.6%) and a partial response in 4/12 (33.3%). Two of 8 patients with a platelet count < 100 x 10(9)/L had a complete response, as did 3/9 with a neutrophil count < 1.5 x 10(9)/L. Compared to rHuEpo or amifostine used as ...